Neurocrine Biosciences, Inc.
596 articles about Neurocrine Biosciences, Inc.
-
Neurocrine Biosciences, Inc. to Present at Deutsche Bank's 2012 dbAccess BioFEST
11/28/2012
-
Neurocrine Biosciences, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
11/21/2012
-
Neurocrine Biosciences, Inc. to Present at Lazard Capital Market's 9th Annual Healthcare Conference
11/7/2012
-
Neurocrine Biosciences, Inc. Reports Third Quarter 2012 Results
11/1/2012
-
Neurocrine Biosciences, Inc. Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
10/25/2012
-
Neurocrine Biosciences, Inc. Announces Start of Phase IIb Study of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
10/2/2012
-
Neurocrine Biosciences, Inc. to Present at the Morgan Stanley Global Healthcare Conference
9/6/2012
-
Neurocrine Biosciences, Inc. Reports Second Quarter 2012 Results
8/1/2012
-
Neurocrine Biosciences, Inc. Announces Conference Call and Webcast to Present Second Quarter 2012 Financial Results
7/26/2012
-
Neurocrine Biosciences, Inc. to Present at the Jefferies and Co. 2012 Global Healthcare Conference
5/29/2012
-
Neurocrine Biosciences, Inc. Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure
5/18/2012
-
Neurocrine Biosciences, Inc. To Present At The Deutsche Bank 37th Annual Health Care Conference
5/7/2012
-
Neurocrine Biosciences, Inc. Reports First Quarter 2012 Results
5/3/2012
-
Neurocrine Biosciences, Inc. Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
5/2/2012
-
Neurocrine Biosciences, Inc. Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4/26/2012
-
Neurocrine Biosciences, Inc. to Present at the 11th Annual Needham Healthcare Conference
3/28/2012
-
Neurocrine Biosciences, Inc. Release: Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012
3/27/2012
-
Neurocrine Biosciences, Inc. Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
3/27/2012
-
Neurocrine Biosciences, Inc. to Present at The 24th Annual Roth Conference
3/8/2012
-
Neurocrine Biosciences, Inc. to Present at the 32nd Annual Cowen and Company Health Care Conference
2/29/2012